Orphazyme ApS, a Copenhagen, Denmark-based developer of novel therapeutics for the treatment of rare and genetic diseases, completed a €20m Series B financing round.
The round was led by Kurma Partners, with participation from and Idinvest Partners joined existing investors Novo A/S, Sunstone Capital and Aescap Venture. In conjunction with the funding, Remi Droller, Managing Partner, will join Orphazyme’s Board.
Led by Anders Hinsby, CEO, Orphazyme develops medicines for the treatment of genetic diseases. The lead program is in preclinical development as treatment for lysosomal storage diseases. This family of genetic disorders consists of more than 45 diseases, most of which are currently untreatable and often fatal.
The company had raised more than €17m in seed and series A financing as follows:
09/09/2011: Orphazyme Completes €14M Series A Financing
27/03/2011: Orphazyme Raises DDK 22M in Seed Financing